Nutraceuticals

Pharmaceutical-grade excellence capturing the $89 billion regulated wellness revolution. Our nutraceuticals division leverages EU-GMP manufacturing to create first-mover advantages through regulatory barriers that competitors cannot meet. As global wellness regulations evolve toward pharmaceutical standards, our manufacturing excellence positions us for dominant market share in markets where quality compliance takes competitors years to achieve.

The $89 Billion Regulated Wellness Revolution

The global CBD nutraceuticals market is experiencing unprecedented evolution toward quality, compliance, and therapeutic efficacy that only pharmaceutical-grade manufacturers can deliver. Projected to reach $89 billion by 2026, this represents market transformation, not just growth, as consumers increasingly demand science-backed wellness solutions with pharmaceutical credibility. Our EU-GMP platform creates defensible competitive advantages as regulatory frameworks globally favor quality standards that establish insurmountable barriers for traditional wellness competitors.

Our pharmaceutical-grade manufacturing excellence creates defensible market positions across the expanding global wellness markets.

Projected Value Distribution

Pharmaceutical-Grade Manufacturing Creating Wellness Market Leadership

Every nutraceutical product derives from our EU-GMP manufacturing processes, ensuring quality consistency that wellness competitors cannot replicate. Zero THC detection with 0.000006% sensitivity (industry's lowest), ICH-Q7 compliance exceeding nutraceutical requirements, and 36-month stability validated under pharmaceutical protocols create complete traceability from cultivation through consumer delivery—establishing premium positioning justified by measurable quality superiority.

Brains Bio’s nutraceutical portfolio is divided into two complementary streams, with all nutraceutical products being free of THC and controlled substances and manufactured with pharmaceutical grade ingredients, ensuring unmatched quality consistency, traceability, and safety:

  • Co-Branded & White-Label Products: Our exclusive multi-year agreement with Vitabiotics, the UK’s #1 vitamin company with 27% market share and distribution across 100+ countries, validates our pharmaceutical-grade approach while providing immediate access to established global networks.
  • Brains Bio-Owned Brands: Three-tier strategy maximizes market capture across all consumer segments. Brains Pure commands premium pricing through exclusive Harrods placement for high-net-worth wellness consumers. Vitabiotics x Brains leverages pharmaceutical credibility across major pharmacy chains with science-backed positioning. Vitality CBD captures price-conscious consumers through Amazon and major retailers, driving volume while maintaining quality standards.

Regulatory Moats Creating Competitive Advantages

UK Market Dominance: Retail locations including Holland & Barrett (Top 3 CBD brand), Day Lewis (Top 2 best-selling), Harrods Pharmacy (exclusive premium placement), plus Tesco, Boots and ASDA. Our validated Novel Foods dossier positions us for first-wave approvals, creating high barriers for non-compliant competitors.

European Expansion: EFSA submission underway following proven UK blueprint, targeting first-mover advantage across 27 EU member states representing 450 million consumers. Priority markets Germany, France, Spain, and Italy collectively represent €200+ billion wellness opportunity.

Japan Strategic Entry: Amended cannabis laws (December 2024) permit pharmaceutical-grade CBD under the world's strictest quality thresholds, creating extraordinary barriers that our compliance capabilities uniquely enable us to meet in Asia's highest-value wellness market.